Comparison between Mahamaya Lifesciences IPO and Solvex Edibles IPO.
Mahamaya Lifesciences IPO is a SME Fixed Price IPO proposed to list at BSE SME while Solvex Edibles IPO is a SME Fixed Price proposed to list at BSE SME.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Oneview Corporate Advisors Pvt.Ltd. | Corporate Makers Capital Ltd. |
| Registrar | Kfin Technologies Ltd. | Maashitla Securities Pvt.Ltd. |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd. | JSK Securities & Services Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Mahamaya Lifesciences IPO is up to ₹66.91 Cr whereas the issue size of the Solvex Edibles IPO is up to ₹17.93 Cr. The final issue price of Mahamaya Lifesciences IPO is ₹114.00 per share and of Solvex Edibles IPO is ₹72.00 per share.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹108.00 per share | |
| Issue Price (Upper) | ₹114.00 per share | |
| Issue Price (Final) | ₹114.00 per share | ₹72.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | 1600 shares |
| Fresh Issue Size | 53,29,200 shares | 24,89,600 shares |
| Fresh Issue Size (Amount) | up to ₹60.75 Cr | up to ₹17.93 Cr |
| OFS Issue Size | 5,40,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹6.16 Cr | up to ₹0.00 Cr |
| Issue Size Total | 58,69,200 shares | 24,89,600 shares |
| Issue Size Total (Amount) | up to ₹66.91 Cr | up to ₹17.93 Cr |
Mahamaya Lifesciences IPO opens on Nov 11, 2025, while Solvex Edibles IPO opens on Sep 22, 2025. The closing date of Mahamaya Lifesciences IPO and Solvex Edibles IPO is Nov 13, 2025, and Sep 26, 2025, respectively.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |
|---|---|---|
| Anchor Bid Date | Nov 10, 2025 | |
| Issue Open | Nov 11, 2025 | Sep 22, 2025 |
| Issue Close | Nov 13, 2025 | Sep 26, 2025 |
| Basis Of Allotment (Tentative) | Nov 14, 2025 | Sep 29, 2025 |
| Initiation of Refunds (Tentative) | Nov 17, 2025 | Sep 30, 2025 |
| Credit of Share (Tentative) | Nov 17, 2025 | Sep 30, 2025 |
| Listing date (Tentative) | Nov 18, 2025 | Oct 01, 2025 |
| Anchor Lockin End date 1 | Dec 13, 2025 | |
| Anchor Lockin End date 2 | Feb 11, 2026 |
Mahamaya Lifesciences IPO P/E ratio is 15.65, as compared to Solvex Edibles IPO P/E ratio of 11.15.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)Solvex Edibles Ltd.'s revenue increased by 90% and profit after tax (PAT) rose by 305% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 77.27 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 56.35 | 70.72 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.65 | 11.15 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹266.82 Cr. | ₹64.45 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 34.94% | 23.69% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.15% | 24.51% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.29 | ₹6.46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 26.19% | 20.28% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mahamaya Lifesciences IPO Retail Individual Investors (RII) are offered 20,59,200 shares while in Solvex Edibles IPO retail investors are offered 20,59,200 shares. Qualified Institutional Buyers (QIB) are offered 11,76,000 shares in Mahamaya Lifesciences IPO and 0 shares in Solvex Edibles IPO.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,52,000 shares | 0 shares |
| Market Maker Reservation | 3,09,600 shares | 1,31,200 shares |
| QIB | 11,76,000 shares | 0 shares |
| NII | 8,82,000 shares | 12,44,800 shares |
| RII | 20,59,200 shares | 12,44,800 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 58,69,200 shares | 24,89,600 shares |
Mahamaya Lifesciences IPO subscribed 1.63x in total, whereas Solvex Edibles IPO subscribed 1.02x.
| Mahamaya Lifesciences IPO | Solvex Edibles IPO | |
|---|---|---|
| QIB (times) | 1.19x | |
| NII (times) | 3.63x | 1.31x |
| Big NII (times) | 5.00x | |
| Small NII (times) | 0.90x | |
| RII (times) | 1.02x | 0.73x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.63x | 1.02x |
